Page last updated: 2024-11-09

iothalamate meglumine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iothalamate Meglumine: A radiopaque medium used for urography, angiography, venography, and myelography. It is highly viscous and binds to plasma proteins. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID656642
CHEMBL ID1201125
CHEBI ID31714
SCHEMBL ID180546
MeSH IDM0011685

Synonyms (73)

Synonym
iothalamate methylglucamine salt
iothalamate meglumine
meglumine iothalamate
methylglucamine iotalamate
iotalamate de methylglucamine [french]
1-deoxy-1-(methylamino)-d-glucitol 5-acetamido-2,4,6-triiodo-n-methylisophthalamate (salt)
1-deoxy-1-(methylamino)-d-glucitol 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)benzoate
conray meglumin
contrix 28
conray 280
conray 30
conray 60
meglumine isothalamate
methylglucamine iothalamate
meglumine conray
iothalamic acid n-methylgucamine salt
conray 43
d-glucitol, 1-deoxy-1-(methylamino)-, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)benzoate (salt)
cysto-conray
conray meglumine 282
iothalamate methylglucamine
conray
meglumine iotalamate
einecs 235-998-9
jotalamsaeure methylglucaminesalz [german]
iothalamate meglumine (usp)
conray (tn)
D01999
13087-53-1
meglumine iotalamate (jp17)
meglumine iotalamate injection
iotalamate meglumine
CHEMBL1201125
meglumine, iotalamate
iothalamate, methylglucamine
meglumine, iothalamate
iothalamic acid methylglucamine
iotalamate, meglumine
methylglucamine, iothalamic acid
iotalamate, methylglucamine
iothalamate, meglumine
iothalamic acid meglumine
meglumine, iothalamic acid
jotalamsaeure methylglucaminesalz
iotalamate de methylglucamine
meglumine iothalamate [ban]
iothalamate meglumine [usp]
cysto-conray ii
unii-xuw72gop7w
xuw72gop7w ,
iothalamate meglumine [usp impurity]
meglumine iotalamate [mart.]
iothalamate meglumine [vandf]
iothalamate meglumine component of vascoray
iothalamic acid n-methylglucamine salt [mi]
iothalamate meglumine [orange book]
vascoray component iothalamate meglumine
iotalamate meglumine [who-dd]
SCHEMBL180546
1-deoxy-1-(methylamino)-d-glucitol 3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoate
iotalamic acid meglumine
CHEBI:31714
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid;6-(methylamino)hexane-1,2,3,4,5-pentol
DTXSID10926949
5-acetamido-2,4,6-triiodo-n-methylisophthalamic acid-methylglucamine
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
Q27294007
AKOS040752095
dtxcid50122347
benzoic acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)-, compound with 1-deoxy-1-(methylamino)-d-glucitol (1:1)
meglumine iotalamate (mart.)
iothalamic acid n-methylglucamine salt
iothalamate meglumine (usp impurity)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The relation between ionic composition and cardiotoxicity of two dimers, iocarmate and iozomate, was investigated by selective injection into the left and right coronary arteries, Least toxic reactions developed at a sodium concentration of 263 to 315 mmol/l for sodium-meglumine iocarmate and 271 to 379 mmol/l for sodium-meglumine iozomate."( Ionic composition and cardiotoxicity of dimeric contrast media at injection into the coronary arteries of rabbits.
Carter, AM; Olin, T, 1976
)
0.26
"The adverse effects following lumbar myelography and ventriculography with meglumine iothalamate (Conray Meglumin), meglumine iocarmate (Dimer-X, Bis-Conray) and metrizamide (Amipaque), and after thoracic and cervical myelography and cisternography with metrizamide are reviewed."( Adverse effects of water-soluble contrast media in myelography, cisternography and ventriculography. A review with special reference to metrizamide.
Skalpe, IO, 1977
)
0.26
"Selective left vertebral angiography was carried out in 21 rabbits comparing the toxic effects of meglumine iothalamate (Conray meglumine), meglumine metrizoate (Isopaque Cerebral) and metrizamide (Amipaque)."( The toxicity of the non-ionic watersoluble contrast medium metrizamide (Amipaque) in selective vertebral angiography. An experimental study in rabbits.
Skalpe, IO, 1977
)
0.26
"0 ml/kg body weight were safe whilst providing optimal diagnostic information."( Safe amounts of contrast medium for angiocardiography in neonates and infants.
Bonvicini, M; Fox, KM; Graham, GR; Patel, RG; Taylor, JF, 1977
)
0.26
"Although Dimer X is said to be a low toxic water soluble contrast medium, epileptic seizures sometimes occur during or after Dimer X ventriculography."( Intracisternal dimer X: toxicity and prophylaxis.
Nishikawa, M; Yonekawa, Y, 1976
)
0.26
" This differential alteration in neurophysiological parameters was independent of changes in blood and cerebrospinal fluid pressure, implying that these water-soluble contrast media have a direct toxic effect on the nervous system, possibly situated in the larger (group 1) root fibers."( Evaluation of the neurotoxicity of water-soluble myelographic contrast agents by electrophysiological monitors.
Allen, WE; Collins, WF; VanGilder, JC, 1976
)
0.26
"The adverse effects in a series of 50 lumbar myelographies with Amipaque were compared with those in a corresponding series, examined with Dimer-X."( Adverse effects of lumbar myelography with amipaque and dimer-X.
Irstam, L; Selldén, U, 1976
)
0.26
" Mechanisms of severe adverse reactions are reviewed, including the views of Lasser and Lalli, and the view that emphasizes the importance of cardiotoxic and hemodynamic effects."( Chemotoxicity of contrast media and clinical adverse effects: a review.
Dawson, P,
)
0.13
" Diatrizoate sodium meglumine was the most toxic agent, followed by diatrizoate and meglumine, iothalamate meglumine, and mannitol in terms of blood-brain barrier (BBB) disruption and coupled perfusion decline."( Comparative neurotoxicity of angiographic contrast media.
Albright, R; Drayer, B; Fram, E; Velaj, R, 1985
)
0.49
" No complications or adverse reactions occurred in either group."( Safety of contrast media in cerebral angiography: iopamidol vs. methylglucamine iothalamate.
Allen, S; Bates, M; Bird, CR; Drayer, BP; Heinz, ER; Osborne, DR; Triolo, PJ; Velaj, R; Yeates, AE,
)
0.13
"This study was designed to determine whether a mixture of iodinated contrast material and gadopentetate dimeglumine used during MR arthrography yields free gadolinium ion, a systemically toxic metal."( Is a mixture of gadolinium and iodinated contrast material safe during MR arthrography?
Brown, RR; Clarke, DW; Daffner, RH, 2000
)
0.31
"Gadopentetate dimeglumine and iodinated contrast material can be mixed before MR imaging without any release of free gadolinium and are therefore safe for confirming the intraarticular placement of contrast material before MR arthrography."( Is a mixture of gadolinium and iodinated contrast material safe during MR arthrography?
Brown, RR; Clarke, DW; Daffner, RH, 2000
)
0.31
"Most studies of the adverse effects of x-ray contrast media used in ERCP have focused on post-ERCP pancreatitis."( Comparative cytotoxicity of low-osmolar nonionic and high-osmolar ionic contrast media to dog gallbladder epithelial cells.
Ju, YM; Kim, JY; Kim, MH; Lee, SK; Min, YI; Seo, DW, 2002
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Some computed tomographic (CT) implications of these pharmacokinetic studies are discussed."( Pharmacokinetics of contrast media: experimental results in dog and man with CT implications.
Berger, N; Gardeur, D; Lautrou, J; Metzger, J; Millard, JC, 1980
)
0.26
"To investigate pharmacokinetic and physiologic factors that determine the time to peak intravenous contrast medium enhancement in computed tomographic (CT) and magnetic resonance (MR) angiography in the porcine mid-abdominal aorta."( Peak contrast enhancement in CT and MR angiography: when does it occur and why? Pharmacokinetic study in a porcine model.
Bae, KT, 2003
)
0.32
" Mathematic and pharmacokinetic analyses were performed to investigate factors that determine peak enhancement."( Peak contrast enhancement in CT and MR angiography: when does it occur and why? Pharmacokinetic study in a porcine model.
Bae, KT, 2003
)
0.32
"Single-center, prospective, open-label, randomized, three-part crossover pharmacokinetic study."( Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
Beringer, PM; Burckart, GJ; Gill, M; Hidayat, L; Kriengkauykiat, J; Liu, S; Louie, S; Rao, PA; Shapiro, B; Synold, T; Zhang, X, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" When combined with computed tomography (CT) of the brain (positive contrast CT ventriculography), these procedures become simpler to perform, the incidence of complications is less, and there is a significant increase in their diagnostic yield."( Positive contrast ventriculography combined with computed tomography: technique and applications.
Baron, MG; Khan, A; Marc, JA; Pillari, G; Rosenthal, A, 1980
)
0.26

Dosage Studied

ExcerptRelevanceReference
" Sixty patients were divided into two groups of 30 patients; one group received Omnipaque in a dosage of 350 mgI/ml and the other group received Telebrix in a dosage of 350 mgI/ml."( Comparative trial of Omnipaque 350 (iohexol) and Telebrix 350 (sodium-meglumine-ioxithalamate) in left ventriculography and coronary arteriography.
Buis, B; Jorgova, J; Sedney, MI; van Benthem, A; van der Wall, EE,
)
0.13
" In the present study the dependence of "CT clearance" on dosage and time was examined in 12 healthy subjects."( [Dose and time dependency of "CT clearance"].
Dexheimer, C; Kaltenborn, HA; Klose, KJ, 1989
)
0.28
" A dose-response curve for the release of glycosaminoglycan by chymopapain was linear when the amount of enzyme was plotted on a logarithmic scale against glycosaminoglycan release."( Effect of X-ray contrast media on the action of chymopapain on the intervertebral disc: an in vitro study of cartilage degradation.
Barrett, AJ; Buttle, DJ; Tudor, J, 1984
)
0.27
" The incidence of eosinophilia was irrespective of dosage or type of RCM."( Eosinophilia caused by iodinated radiographic contrast media.
Kuzmanić, D; Plavsić, B; Rotkvić, I, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amidobenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (568)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990413 (72.71)18.7374
1990's99 (17.43)18.2507
2000's41 (7.22)29.6817
2010's15 (2.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.69 (24.57)
Research Supply Index6.63 (2.92)
Research Growth Index3.97 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials69 (10.03%)5.53%
Reviews11 (1.60%)6.00%
Case Studies84 (12.21%)4.05%
Observational0 (0.00%)0.25%
Other524 (76.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]